- Home
- PTGX vs RCKT Comparison
PTGX vs RCKT Comparison
Compare PTGX & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTGX | RCKT |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | United States | United States |
| Employees | N/A | 202 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 401.6M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | PTGX | RCKT |
|---|---|---|
| Price | $99.99 | $3.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 14 |
| Target Price | ★ $108.23 | $29.73 |
| AVG Volume (30 Days) | 630.7K | ★ 3.8M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $874.25 | N/A |
| Revenue Next Year | N/A | $64.28 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $41.29 | $2.19 |
| 52 Week High | $107.84 | $8.26 |
Technical Indicators
Market Signals| Indicator | PTGX | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 47.48 | 41.22 |
| Support Level | $95.40 | $3.32 |
| Resistance Level | $100.00 | $4.08 |
| Average True Range (ATR) | 4.19 | 0.19 |
| MACD | -0.63 | 0.01 |
| Stochastic Oscillator | 39.57 | 25.17 |
Price Performance
Historical ComparisonAbout PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.